NEW YORK and LONDON, January 12, 2015
Phase II dose ranging clinical trial in atopic dermatitis expected to begin in first quarter of 2015
Celsus Therapeutics (NASDAQ: CLTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis.
